Associated Myocarditis: A Predictive Factor for Response?
Immune checkpoint inhibitors
Ipilimumab
Melanoma
Myocarditis
Nivolumab
Pembrolizumab
Journal
Case reports in oncology
ISSN: 1662-6575
Titre abrégé: Case Rep Oncol
Pays: Switzerland
ID NLM: 101517601
Informations de publication
Date de publication:
Historique:
received:
13
03
2020
accepted:
16
03
2020
entrez:
11
6
2020
pubmed:
11
6
2020
medline:
11
6
2020
Statut:
epublish
Résumé
In the present case report, we aimed to describe 2 cases of myocarditis occurring as serious adverse effects of immune checkpoint inhibitors (ICIs) administered as treatment for metastatic melanoma. We describe 2 female patients: an 81-year-old treated with pembrolizumab and a 55-year-old treated with a combination of nivolumab and ipilimumab. Both patients underwent resection of metastases; while under treatment, both developed myocarditis, most probably as a toxicity from pembrolizumab and nivolumab plus Ipilimumab, respectively. While they achieved complete response, the occurrence of myocarditis as a toxicity of ICIs may have been a predictive sign that the immune system was sufficiently activated by the checkpoint inhibitor therapy to induce complete remission.
Identifiants
pubmed: 32518552
doi: 10.1159/000507278
pii: cro-0013-0550
pmc: PMC7265708
doi:
Types de publication
Case Reports
Langues
eng
Pagination
550-557Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764
pubmed: 29567210
Oncologist. 2018 Aug;23(8):879-886
pubmed: 29802219